Merck’s (NYSE: MRK) Q2 2026 results reflect continued strength in oncology and animal health, plus increasing contributions from launches. Our company announced Q2 worldwide sales of $16.6 billion.
“We continued to make substantial progress across our business this quarter, driven by strong execution and growing contributions from new product launches,” said Rob Davis, chairman and CEO. “The FDA approval of LIPFENDRA is an exciting moment for our company and for patients. Together with key regulatory and clinical advances across oncology, HIV and immunology, this achievement reflects the strength of our pipeline and portfolio transformation as we bring forward the next wave of innovation. I am confident in the ongoing execution of our strategy as we deliver for patients and further enhance our long-term growth trajectory.”
Merck anticipates full-year 2026 worldwide sales to be between $66.3 billion and $67.3 billion.
Take a look at the infographic below for more details on Q2 2026 results.
